Urolithiasis in HIV-positive patients treated with atazanavir

被引：72

作者：

Couzigou, Carine

Daudon, Michel

Meynard, Jean Luc

Borsa-Lebas, Francoise

Higueret, Denise

Escaut, Lelia

Zucman, David

Liotier, Jean-Yves

Quencez, Jean-Louis

Asselah, Karine

May, Thierry

Neau, Didier

Vittecoq, Daniel

机构：

[1] Hop Paul Brousse, AP HP, Serv Malad Infect & Trop, F-94804 Villejuif, France

[2] Hop Necker Enfants Malad, AP HP, Biochim Lab, Paris, France

[3] Hop St Antoine, AP HP, Serv Malad Infect & Trop, F-75571 Paris, France

[4] CHU Rouen, Serv Malad Infect & Trop, Rouen, France

[5] Hop Pellegrin, Biochim Lab, F-33076 Bordeaux, France

[6] Hop Pellegrin, Fed Maladies Infect & Trop, F-33076 Bordeaux, France

[7] CHU Nancy, Serv Malad Infect & Trop, Nancy, France

来源：

CLINICAL INFECTIOUS DISEASES | 2007年 / 45卷 / 08期

关键词：

D O I：

10.1086/521930

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Among protease inhibitors, atazanavir has not been associated with urolithiasis in clinical studies. We describe 11 cases of atazanavir-associated urolithiasis in patients with human immunodeficiency virus (HIV) infection. Patients with low water intake, high urinary pH, and a prior history of urinary stones may have a higher risk of atazanavir-associated urine crystallization.

引用

页码：E105 / E108

页数：4

共 10 条

[1]

Breilh D, 2007, PROGR 14 C RETR OPP, P433

[2] Acute interstitial nephritis associated with atazanavir, a new protease inhibitor [J].